Results 191 to 200 of about 186,761 (273)

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. [PDF]

J Int Med Res
Chan KH, Cen P, Shu T, Canfield S, Zhao H, Gonzalez A, Rowe J, Tammisetti V, Ayoub H, Blanco A, Amsbaugh M, Tannir N.   +11 more
europepmc   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. [PDF]

Radiol Imaging Cancer
Siddiqi NS.
europepmc   +1 more source

A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). [PDF]

Clin Cancer Res
Niravath P, Uzair I, Sun K, Mai H, Guan J, Li M, Deng J, Qian W, Zhou J, Guzman L, Banaglorioso K, Hashmani R, Mathur S, Chang J.   +13 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Effectiveness of neoadjuvant chemotherapy with lenvatinib plus pembrolizumab in advanced endometrial cancer: a case report. [PDF]

J Med Case Rep
Konnai K, Fujiwara H, Notomi T, Yoshikawa C, Yokozawa T, Saji H.   +5 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

A case series of hypercalcemia associated with pembrolizumab therapy: evidence for a calcitriol-mediated mechanism. [PDF]

JCEM Case Rep
Belcher V, Barghouthi N, Hadique S, Woomer H, Wong Z, Haider A.   +5 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source